Compare JVA & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | LEXX |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 22.7M |
| IPO Year | 2005 | N/A |
| Metric | JVA | LEXX |
|---|---|---|
| Price | $3.72 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 41.4K | ★ 207.6K |
| Earning Date | 09-12-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.91 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $89,748,681.00 | $705,923.00 |
| Revenue This Year | N/A | $46.98 |
| Revenue Next Year | N/A | $17.26 |
| P/E Ratio | $11.45 | ★ N/A |
| Revenue Growth | 17.92 | ★ 49.85 |
| 52 Week Low | $2.75 | $0.77 |
| 52 Week High | $9.93 | $2.85 |
| Indicator | JVA | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 55.22 |
| Support Level | $3.32 | $1.00 |
| Resistance Level | $3.84 | $1.15 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.18 | 59.50 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.